Abstracts

An SMS intervention to Improve HIV Linkage to Care: A Randomized Comparative Effectiveness Trial

Background: Up to 50% of HIV-infected persons in sub-Saharan Africa are lost from care between HIV diagnosis and ART initiation. Methodology: We enrolled participants in a comparative effectiveness trial to improve linkage to care at a publicly operated HIV clinic in Mbarara, Uganda. Clinicians identified patients undergoing high-risk CD4 testing, defined as a test for…

Carotid Distensibility and Immune Activation in HIV-Infected Patients Without Coronary Calcium

Background: Coronary artery calcification (CAC) scoring significantly improves cardiovascular risk stratification; however, CAC is a late finding of atherosclerotic vascular disease. Increased vascular stiffness (i.e. decreased distensibility) may be an early marker of vascular disease in HIV-infected patients on antiretroviral therapy (ART) prior to the development of vascular calcification. The relationship of chronic systemic immune…

Monocyte but not Cellular Activation is Associated with Coronary Atherosclerosis in the MACS

Background: Immune activation is a proposed mechanism for increased cardiac risk in HIV infection. We hypothesize that virally suppressed HIV-infected patients have higher CD8+ T cell and monocyte activation than uninfected controls, and that these measures are associated with coronary atherosclerosis. Methodology: Cross-sectional analyses of HIV-uninfected (n=71) and virally suppressed HIV-infected (n=95) men in Los…

Impact of Low CD4 Count and HIV Persistence on Endothelial Function in Patients With Low Plasma RNA

Background: Chronic inflammation contributes to increased cardiovascular (CV) risk among HIV-infected individuals with low plasma viral RNA levels. Hyperemic velocity (HV), a measure of microvascular function, is the stimulus for brachial artery flow-mediated vasodilation (FMD), a measure of macrovascular function. HV is more predictive of CV events than FMD in the general population. The contribution…

Microvascular Disease in Controllers Is Mediated by HIV DNA and Immune Dysfunction

Background: HIV-infected individuals (“controllers”) who are able to maintain low levels of plasma RNA in the absence of antiretroviral therapy (ART) have stable low-level viremia, elevated T cell activation, and a higher risk of cardiovascular disease (CVD). The mechanisms underlying this increased risk are unknown but may include low-level viral replication leading to chronic inflammation…

Zinc-finger Endonuclease Targeting LEDGF/p75 Inhibits HIV-1 Integration

Background: Human immunodeficiency virus (HIV) requires several host factors to complete viral replication cycle. Genome editing using zinc-finger nucleases (ZFN) has been successfully applied to disrupt CCR5 or CXCR4 host factors, inhibiting viral entry and infection. Lens epithelium-derived growth factor (LEDGF/p75) is a lentivirus-specific cellular cofactor which directly interacts with viral integrase, tethering viral preintegration…

HIV IntegraseR263A/K264A Is Defective for TRN-SR2/IN Interaction and Nuclear Import of the PIC

Background: Transportin-SR2 (TRN-SR2/TNPO3) is a human karyopherin encoded by the TNPO3 gene. We identified TRN-SR2 as a binding partner of HIV-1 integrase (IN) and validated TRN-SR2 as an important cellular cofactor for the nuclear import of HIV-1. However, the question still remained whether the direct interaction between TRN-SR2 and IN mediates the nuclear import of…

BET Proteins Mediate Integration Site Selection of MLV Much Alike LEDGF/p75 in HIV Integration

Background: A hallmark of retroviral replication is stable integration of the viral genome in the host cell DNA. However, retroviruses do not integrate at random. Mediated by LEDGF/p75, lentiviruses preferentially integrate in the body of active transcription units. Gammaretroviruses, including Moloney Murine Leukemia Virus (MLV), favour transcription start sites and CpG islands. It is generally…